TFB 00640
Alternative Names: TFB-00640Latest Information Update: 02 Dec 2025
At a glance
- Originator ThirtyFiveBio
- Class Anti-inflammatories; Small molecules
- Mechanism of Action GPR35 protein antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders; Ulcerative colitis
Most Recent Events
- 16 Oct 2025 Preclinical trials in Gastrointestinal disorders in United Kingdom (PO) prior to October 2025 (ThirtyFiveBio pipeline, October 2025)
- 16 Oct 2025 Preclinical trials in Ulcerative colitis in United Kingdom (PO) prior to October 2025 (ThirtyFiveBio pipeline, October 2025)
- 16 Oct 2025 ThirtyFiveBio plans a phase I trial for Ulcerative colitis in 2026 (ThirtyFiveBio pipeline, October 2025)